Biochemical Pharmacology, 158, 413-424. Elsevier Inc. Bobkov, V, Zarca, A M, van Hout, A, Arimont, M, Doijen, J, Bialkowska, M, Toffoli, E, Klarenbeek, A, van der Woning, B, van der Vliet, H J, van Loy, T, de Haard, H, Schols, D, Heukers, R & Smit, M J 2018, ' Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions ', Biochemical Pharmacology, vol. 158, pp. 413-424 . https://doi.org/10.1016/j.bcp.2018.10.014 Biochemical Pharmacology Bobkov, V, Zarca, A M, Van Hout, A, Arimont, M, Doijen, J, Bialkowska, M, Toffoli, E, Klarenbeek, A, van der Woning, B, van der Vliet, H J, Van Loy, T, de Haard, H, Schols, D, Heukers, R & Smit, M J 2018, ' Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions ', Biochemical Pharmacology, vol. 158, pp. 413-424 . https://doi.org/10.1016/j.bcp.2018.10.014
Biochemical Pharmacology, 158, 402-412. Elsevier Inc. Van Hout, A, Klarenbeek, A, Bobkov, V, Doijen, J, Arimont, M, Zhao, C, Heukers, R, Rimkunas, R, de Graaf, C, Verrips, T, van der Woning, B, de Haard, H, Rucker, J B, Vermeire, K, Handel, T, Van Loy, T, Smit, M J & Schols, D 2018, ' CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry ', Biochemical Pharmacology, vol. 158, pp. 402-412 . https://doi.org/10.1016/j.bcp.2018.10.015 Biochemical Pharmacology